FindTrial
Sign In

The efficacy and safety of ambroxol hydrochloride in the treatment of novel coronavirus pneumonia (COVID-19): a retrospective medical based study

The efficacy and safety of ambroxol hydrochloride in the treatment of novel coronavirus pneumonia (COVID-19): a retrospective study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038160
Enrollment
Unknown
Registered
2020-09-11
Start date
2020-09-11
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

1:ambroxol hydrochloride treatment
2:without ambroxol hydrochloride treatment

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. patients with novel coronavirus infection have been diagnosed; 2. aged >=18 years.

Exclusion criteria

Exclusion criteria: (1) cases who had been transfered to other hospitals for further treatment; (2) Cases whose data are incomplete and cannot be accurately dialectical.

Design outcomes

Primary

MeasureTime frame
the number of patients with aggravation of disease;—

Secondary

MeasureTime frame
COVID-19 RT-PCR negative convertion time;duration of invasive mechanical ventilation;—

Countries

China

Contacts

Public ContactHong Cheng

Zhongnan Hospital of Wuhan University

chenghong@znhospital.cn+86 13387660579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026